Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,058Revenue $M3.4Net Margin (%)-12,025.9Altman Z-Score24.0
Enterprise Value $M813EPS $-0.8Operating Margin %-12,097.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score3.5Pre-tax Margin (%)-12,025.9Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %-33.0Quick Ratio10.5Cash flow > EarningsY
Price/Sales1,1705-y EBITDA Growth Rate %-3.2Current Ratio10.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-44.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-47.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M136ROIC % (ttm)-616.6Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 7.76122%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 7.76168%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 7.766%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 7.76-19%Reduce 50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 7.7626%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 7.7622%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
VITULLO NICOLEDirector 2015-08-14Sell37,843$7.513.33 view
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-51.5 view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-48.27 view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.2-23.92 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-30.53 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-31.27 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.96 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.45-37.67 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.63-33.28 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.33-31.51 view

Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
    Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 

    More From Other Websites
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 24 2015
    ACHILLION PHARMACEUTICALS INC Financials Aug 20 2015
    Achillion Pharmaceuticals (ACHN) Jumps: Stock Gains 16.7% Aug 18 2015
    Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites Aug 15 2015
    Is It Time For Gilead Sciences To Buy Achillion? Aug 14 2015
    10-Q for Achillion Pharmaceuticals, Inc. Aug 12 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
    Achillion reports 2Q loss Aug 10 2015
    Achillion reports 2Q loss Aug 10 2015
    Achillion Reports Second Quarter and Six Month 2015 Financial Results Aug 10 2015
    Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir... Aug 03 2015
    What Will Gilead Buy Next? 4 Possible Targets Jul 15 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 01 2015
    Achillion to Present at the JMP Securities Life Sciences Conference 2015 Jun 18 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 08 2015
    Billionaire Steve Cohen Bullish Again (And Now More Than Ever) On Achillion Pharmaceuticals, Inc.... May 31 2015
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 27 2015
    The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion... May 21 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK